A*STAR Institute of Molecular and Cell Biology (A*STAR IMCB)

A study implicates novel genetic risk factors in a rare and aggressive lymphoma affecting Asian populations.

Clinicians and scientists have discovered a rare mutation that impairs the immune system, and are using their findings to devise treatment strategies

Antibodies that recognize the SARS-CoV-2 spike protein show potential for diagnosing COVID-19.

The presence of memory T cells in COVID-19-recovered patients hints at their importance in COVID-19 immunity.

A*STAR researchers have developed a biodegradable polymeric drug carrier that can target cancerous tissue in the lungs and liver.

Antiviral strategies against COVID-19 broadly fall into two groups: those that target the virus and those that target the host factors that are essential for virus replication.

Tipped off by artificial intelligence, a research team is testing whether a rheumatoid arthritis drug could be repurposed as a COVID-19 treatment.

Stem cell experts recognize the potential of exosomes for treating COVID-19 pneumonia, but caution that rigorous clinical testing is needed.

Modifying how embryonic stem cells use sugar can switch them into a totipotent state, A*STAR researchers say.

Just because a molecular target resides inside a cancer cell does not mean that it cannot be targeted by antibodies, says Qi Zeng, founder of A*STAR spin-off company Intra-ImmuSG.

Mutations accelerating the degradation of the protein gelsolin are responsible for amyloid plaque buildup in patients suffering from familial amyloidosis, Finnish type.

A*STAR researchers have figured out the detailed structure of a type of protein filament responsible for tethering and moving DNA in bacteria cells.